For the hundreds of millions of people living with chronic hepatitis B, treatment has always meant medication without end. An experimental drug called bepirovirsen may change that. In two international studies, about one in five patients who received the drug were able to stop all therapy while keeping the virus suppressed — an outcome doctors call a functional cure, and one never achieved by a placebo group in the trials.
How bepirovirsen attacks the virus
Developed by GSK with Ionis Pharmaceuticals, bepirovirsen binds to the virus’s genetic material, simultaneously suppressing its replication and cutting production of the surface protein the virus uses to exhaust the immune system. That double action appears to give the body’s defences a chance to regain control. The trials enrolled 1,838 patients, who received weekly injections of the drug or a dummy shot for six months on top of their regular pills, according to the Associated Press report on the results.
A remission that seems to last
In roughly 20 per cent of treated patients, the virus remained undetectable six months after all treatment stopped, and follow-up of earlier study participants suggests most are still doing well up to three years on. Independent experts quoted in the New England Journal of Medicine called the findings a major step, while cautioning that longer observation is needed to see how durable the effect proves across different patient groups.
The numbers behind the disease explain the excitement. The World Health Organization estimates that around a quarter of a billion people live with chronic hepatitis B, and the virus contributes to roughly a million deaths a year through cirrhosis and liver cancer, despite an effective vaccine existing for newborns. A treatment that durably switches the virus off would be the first major therapeutic leap in decades. Health economists add that finite therapy could prove cheaper for health systems than funding suppressive pills for entire lifetimes, particularly where generic drug supply is unreliable and clinic visits are difficult for patients to sustain.
Why a functional cure matters
Current hepatitis B drugs suppress the virus but rarely clear it, leaving patients on lifelong therapy with ongoing risks of liver damage and cancer. A finite course of treatment that ends in lasting control would transform care, especially in regions where the disease is most common and lifelong medication hardest to sustain. More health breakthroughs are covered in our blog reporting. The drug is under fast-track review by the US Food and Drug Administration.
A one-in-five success rate is not the finish line, but it is the first credible sight of one. For a disease defined by indefinite treatment, bepirovirsen offers something patients have never had: an ending.
